TIPS in the Management of Portal Hypertension Clinician s Opinion
|
|
- Blaise Chandler
- 5 years ago
- Views:
Transcription
1 TIPS in the Management of Portal Hypertension Clinician s Opinion Oliviero Riggio 5 th AISF post meeting course Diagnostic and Therapeutic Procedures in Hepatology 2012
2 Oliviero Riggio Dipartimento di Medicina Clinica Sapienza Università di Roma Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione e che la presentazione non contiene discussione di farmaci in studio o ad uso off-label
3 TIPS : well established indications Active variceal bleeding uncontrolled by medical and endoscopic treatment Prevention of variceal rebleeding* Refractory ascites* *RCTs and metanalysis available
4 Variceal bleeding uncontrolled by medical and endoscopic treatment % Efficacy of drugs or endoscopic treatments in the control of variceal bleeding Pool of RCTs 48 No treatment 12 RCTs 319 pts. 74 Drugs 31 RCTs 982 pts 89 Endoscopy 24 RCTs 571 ppts Emergent surgery (PCA or oesophageal transection) has a high mortality rate (about 50%). Patients at greater risk of failing emergent medical and endoscopic treatment are also those least likely to tolerate surgery. Thus, patients who continue to bleed may have a mortality rate as high as 90% (in Child B or C).
5 TIPS in the treatment of uncontrolled variceal bleeding A uthor P atients N C hild C % C ontrol of bleeding % E arly rebleeding N M ortality (40 days) % M cc orm ick Jalan Sanyal G erbes C hou 112 (28 G V ) B anares 56 (19 G V ) B arange K 32G V
6 Acute Bleeding AASLD practice guideline on: TIPS (Hepatology 2005 and 2009) On Prevention and Management of Gastroesophageal Varices and Variceal Hemorrage in Cirrhosis (Hepatology 2007) TIPS is indicated in patients in whom hemorrhage from esophageal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy (Class I, Level C)
7 Prevention of variceal rebleeding (RCTs) Author Control treatment Patients included Cabrera J. EVS 31/32 Rossle M. EVS + Beta-block 61/65 Sanyal AJ. EVS 40/39 Cello JP EVS 21/19 Merli M. EVS 38/43 Sauer P EVS + Beta-block 42/41 Vinel P EVS + Beta-block 32/33* Jalan R. Ligation 31/27 Pomyer-Lelargues G Ligation 41/39 Garcia-Villareal EVS 22/24 Escorsell A P + I 47/44 EVS= Endoscopic Variceal Sclerotherapy; P+I=Propranolol +Isosorbide Mononitrate
8 META-ANALYSIS OF RCTs ON TIPS vs ENDOSCOPIC THERAPY FOR THE PREVENTION OF VARICEAL REBLEEDING TIPS better Endoscopy better RECURRENT BLEEDING MORTALITY ENCEPHALOPATHY Pooled rate difference
9 AASLD practice guideline on: TIPS (Hepatology 2005) On Prevention and Management of Gastroesophageal Varices and Variceal Hemorrage in Cirrhosis (Hepatology 2007) Prevention of rebleeding TIPS should not be used for the prevention of rebleeding in patients who have bled only once from esophageal varices, and its use should be limited to those who fail pharmacological and endoscopic therapy (evidence: grade I)
10 REPORTED REBLEEDING RATES IN RCTs OF DIFFERENT TREATMENTS TO PREVENT VARICEAL REBLEEDING (25 75 percentile) Surgery TIPS B-Bloc+ISMN EVL EVS + B-Bloc EVS B-Blockers Untreated % J Bosch Lancet 2003
11 in patients with a first bleeding from varices TIPS Is considered a rescue therapy for patients with acute bleeding refractory to medical and endoscopic treatment BUT 10 20% of acute bleeders do not respond to first line therapy and rescue-tips mortality rate is still high (14 55% of Pts.) TIPS Is considered a second line treatment for the prevention of rebleeding and should not be used in those who bled only once BUT 20-55% of patients will rebleed within one year after the first line therapy for prevention of rebleeding
12 Poor evolution (n=23) = failure to control bleeding (n=7) or early rebleeding (n=16)
13 Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding Monescillo A. Hepatology, October 2004.
14 Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Monescillo A. Hepatology, October NS p<.0001
15 Methods: Retrospective cohort from 4 centers including 117/221 patients with AVB in whom HVPG was measured within 48 h of admission ( ). The main endpoint was 5-day failure, a composite of uncontrolled bleeding, early rebleeding or death within 5 days Relationship between HVPG and Child-Pugh class and outcome according to HVPG 20 mmhg Abraldes J, J Hepatol 2008;48: ; Editorial
16 Multivariable analysis of prognostic indicators for 5-day failure and ROC curves Variable OR 95% CI Model with all variables HVPG P20 mmhg Systolic blood pressure < Non-alcoholic etiology Model excluding HVPG Child B vs A Child C vs A Systolic blood pressure < Non-alcoholic etiology
17 Background: cirrhotic patients in Child-Pugh class B-C with acute varicel bleeding (AVB) have a poor prognosis despite the use of rescue TIPS Aim: to evaluate if an early decision for PTFE-TIPS in such high risk bleeders could decrease treatment failure and mortality Methods: 63 B-C cirrhotic patients with AVB treated with vasoactive drugs plus band ligation (BL), randomized within 72 hrs of admission,to PTEF-TIPS or continue vasoactive drugs+bl followed by β- Blockers+IMN+BL. Follow-up 16 months Endpoints: failure to control AVB, 1-yr failure, 1-yr survival, safety and complications
18 Results and conclusions (Garcia-Pagan et al) Failure to control AVB Medical (n=31) TIPS (n=32) yr failure (cum %) 97% 50% < yr mortality yr ascites (cum%) 33% 13% yr PSE (cum%) 40% 28% NS Conclusions In high risk cirrhotic patients with AVB, early treatment with PTFE-TIPS is associated with significant marked reductions in rebleeding and mortality. P
19 In any patients with variceal bleeding Evaluate if the risk the of treatment failure and of early rebleeding is high Child-Pugh C (score<14) or Child-Pugh B with active bleeding at endoscopy
20 Baveno V Treatment of Acute Bleeding New statement An early TIPS (ideally < 24 hours) should be considered in patients at high-risk of treatment failure ( e.g. Child-Pugh class C but <14 points or Child class B with active bleeding) after initial pharmacological and endoscopic therapy. (1b;A)
21 TIPS has been used in the following clinical settings Active variceal bleeding uncontrolled by medical and endoscopic treatment Prevention of variceal rebleeding* Refractory ascites* Budd-Chiari syndrome Refractory hepatic hydrotorax Severe venoocclusive disease following bone marrow transplantation Hepato-renal Hepato-pulmonary syndrome *RCTs available
22 Revised Diagnostic Criteria for Refractory Ascites
23 Actuarial Probability of Refractory Ascites Planas R Clin Gastroenterl Hepatol 2006 Probability of survival among patients with Ascites, Refractory Ascites or Hepato-Renal Syndrome Gines P N Engl J Med 2004 Ascites
24 TERAPIA DELLA ASCITE REFRATTARIA: 1. TRAPIANTO 2. PARACENTESI EVACUATIVE RIPETUTE CON INFUSIONE Escludere refrattarietà DI ALBUMINA apparente o transitoria 3. SHUNT INTRAEPATICO PORTO-SISTEMICO TRANSGIUGULARE (TIPS) 4. SHUNT PERITONEO-GIUGULARE DI LEVINE Ascites Club 2010, AASLD 2009
25 PSEUDO-REFRACTORY ASCITES PROBLEM Treatement with loop diuretics only or with insufficient doses of antimineral-corticoids Overdiuresis (negative fluid balance >900 ml/day) leading to prerenal azotemia Renal function impaired by iatrogenic (FANS, ACEinhibitors, nephrotoxic drugs) or cuncurrent complications (vomiting, diarrhoea, bleeding, infection) POSSIBLE RESOLUTION Adjust the dose of diuretics Diuretic withdrawal Withdrawal or treat Uncompliance to sodium restriction Appropriate counselling
26 HVPG modifications after TIPS N of Patients = mmhg Pre Post
27 Effetti del TIPS sulla escrezione urinaria di sodio e sulla funzione renale 45 6 Sodiur ia (microm /min) P<0.04 Creatinina (mg/dl) 4 2 P< Base 24 ore 30 giorni 0 Base 7 giorni 30 giorni Wong F. Ann.Intern Med Guevara M. Hepatology 1998
28 OPPURE 5 studi controllati randomizzati confronto tra TIPS e paracentesi evacuativa + albumina pazienti con ascite refrattaria o ricorrente
29 RCTs TIPS vs PARACENTESIS Characteristics of the patients Trial N Patients TIPS/Para Age Child-Pugh score Alcohol origin Lebrec * /12 50/ /9.2 77%/83% Rossle /31 54/61 9.1/ %/74% Gines /35 59/56 9.3/9.2 51%/60% Sanyal /57 56/52 9.2/9.3 61%/58% Salerno /33 58/60 9.4/9.4 45%/39% *TIPS in 10 pts.
30 RCTs: TIPS vs PARACENTESIS Control of ascites and incidence of HE Trial Definition Control of ascites Encephalopathy Lebrec 1996 No ascites 61 vs 0% p=0.05 Rossle 2000 No ascites 79 vs 24% p= Gines 2002 Sanyal 2002 Salerno 2004 Recurrence of ascites Recurrence of tense ascites >4 para. in un mese 49 vs 83% p= vs 84% p= vs 57% p= pz. vs 0 pz NS 58 vs 48% NS Severe: 60 vs 34% p= 0.03 Severe: 38 vs 12% NS 63 vs 43 % NS Severe p=0.04
31 RCTs: TIPS vs PARACENTESIS Two-years survival rates Trial TIPS PARA p = Transplanted during the study Lebrec % 0% in Child C 60% vs 1 Rossle %^ 32% vs 2 Gines % 26% NS 7 vs 7 Sanyal %* 63%* NS 16 vs 17 Salerno % 29% 0.02* 4 vs 4 ^ TIPS related to better survival at the multivariate analysis *Difference in survival rate manteined in Child C pts (70% of pts.)
32
33 EASL Clinical Practice Guidelines: J. Hepatology 2010 Repeated paracentesis plus albumin (8 g/l of ascites removed) is the first line of treatment. TIPS is effective but associated with a high risk of HE and does not convincingly improve survival compared to repeated paracentesis. TIPS cannot be recommended in patients with severe liver failure (serum bilirubin >5 mg/dl, INR >2 or Child-Pugh score >11).
34 AASLD Practice Guidelines: Hepatology 2009 TIPS may be considered in appropriately selected patients who meet criteria similar to those of published randomized trials. Age > yrs. Previous or present Hepatic Encephalopathy Bilirubin > 3 10 mg/dl (CPS> 11 in one RCT) Renal failure (creatinine >1.5 3mg/dl) Cardiac failure (not better defined)
35
36 Validation cohort Probability of survival among patients with Refractory Spanish (external) cohort Ascites Gines P N Engl J Med 2004
37 Bilirubin < 3 mg/dl Creatinin < 1.9 mg/dl) Child-Pugh < 11
38 Early TIPS for Ascites Ongoing prospective, multi-center, randomized comparison of TIPS with covered stents to Large Volume Paracentesis (LVP) for the treatment of difficult to treat ascites Lack of response to at least 80 mg of furosemide and 200 mg aldactone leading to a paracentesis of >5 liters Ascites recurrence requiring paracentesis of >5 liters within 45 days after therapeutic paracentesis of >5 liters At least one paracentesis of 5 liters in addition to a complication of diuretic therapy (serum sodium < 130 mmol/l or creatinine > 1.8 mg/dl) within the last 90 days
39 Characteristics of post-tips HE: HE is frequent in the first months but generally improves during follow-up Either precipitant induced or spontaneous episodes may occur Sympthoms are generally mild but might also be severe and cause hospitalization The majority of episodes are successfully treated with medical therapy Chronic recurrent HE may occur in 3-10% of patients Cumulative incidence Survivorship: S(t) 1,000 0,750 0,500 0,250 N = 160 0,000 0,0 25,0 50,0 75,0 100,0 Months
40 Prevention of post-tips HE Actuarial rate of patients free of hepatic encephalopathy No treatment Lactitol Rifaximin ,00 Patients free of HE 0,75 0,50 0,25 p = Time (days) Riggio O. J Hepatol. 2005
41 INTRACTABLE HEPATIC ENCEPHALOPATHY AFTER TIPS WITH PTFE-COVERED STENT-GRAFT Incidence rate: 8% 400 TIPS Shunt reduction ,9 Ammonia (µg/dl) Ammonia PSE-index 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 PSE-index Days
42
43 Shunt reduction
44 OUTCOME AFTER SHUNT REDUCTION Pts Reason for shunt reduction TIPS indication Time to shunt reduction (months) HE amelioration Relapsed complication Outcome 1 5 HE episodes (III-IV grade) in 2 months + Persistent HE Ascites 2.4 Yes Yes OLT 2 5 HE episodes (III-IV grade) in 2.5 months Variceal bleeding 28.6 Yes Yes Death for variceal bleeding 3 13 HE episodes (with many hospitalizations) in 17 months + Persistent HE Ascites 37.5 Yes No Alive 4 4 HE episodes (III-IV grade) in 3.7 months + Persistent HE Variceal bleeding 33.7 Yes No Alive 5 3 HE episodes (2 of III-IV grade) in 3 months + Persistent HE 6 4 HE episodes in 3 months + Persistent HE Ascites 10.6 Yes No Death (at 18 months) Ascites 3.2 Yes No Death (at 22 months)
45 Studies N with refractory HE/ Treated with TIPS N of Pts. improved Adverse Events after TIPS reduction Cookson DT /NR 5 Bleeding 3 Deaths 2 Fanelli F / Ascites 1 OLT 1 Deaths 4 Riggio O /78 6 Ascites 1 Death for bleeding 1 Chung HH /113 4 Maleux G / Ascites 1 Bleeding 1 OLT 1 Maleux G / Ascites 1 Hydrothorax 1 Kochar N / Bleeding 3 Ascites 3 Deaths 15 Karlan RK /NR 4 Bleeding 1
46 Factors influencing the decision of reducing the diameter of the shunt in patients with refractory HE after TIPS Factors Strict definition of refractory post TIPS hepatic encephalopathy Suggestions - At least three episodes of nonprecipitant-induced severe encephalopathy requiring hospitalization in the last 3 months despite continuous treatment with nonabsorbabledisaccharides; or - Persistent HE, defined as the presence of a continuously detectable altered mental state despite protein restriction to 1 g/kg of body weight and treatment with nonabsorbable disaccharides
47 Factors influencing the decision of reducing the diameter of the shunt in patients with refractory HE after TIPS Factors Causal relationship between the shunt and HE Suggestions Likely if: - short distance between the onset of refractory HE and TIPS implantation - Low portal systemic gradient supporting the importance of blood diversion Unlikely if - Clinical signs of portal hypertension before revision - Deterioration of liver function after TIPS
48 Factors influencing the decision of reducing the diameter of the shunt in patients with refractory HE after TIPS Factors Low risk of variceal bleeding Suggestions - Check the varices before and after the shunt revision - Start preventive treatment after the revision
49
50 Tiziano, Sacred and Profane Love Galleria Borghese, Roma
Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationInvasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan
Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la
More informationComplication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
More informationTIPS. D Patch Royal Free Hospital London UK
TIPS D Patch Royal Free Hospital London UK TIPS Technique Ascites Budd Chiari Variceal Bleeding Historical Experimental Development 1967 Piccone Shunt between recanalized umbilical vein and saphenous
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationth Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26
44 th 44 th Annual AISF Meeting Rome, February 23 rd -26 th th, 2011 Update on the Baveno Consensus Conference Roberto de Franchis Department of of Clinical Sciences, University of of Milan, Head, Gastroenterology
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationPazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt
Monotematica AISF 2013 Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum, Università di Bologna Pisa, 17-19
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationCase Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Thank you to Marika Rudler, Dominique Thabut, Adrian Gadano, and Jaime Bosch for
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationBarbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana
STROKOVNI SESTANEK ZDRUŽENJA HEMATOLOGOV SLOVENIJE IN ZDRUŽENJA ZA TRANSFUZIJSKO MEDICINO, Terme Zreče, 17.-18.4.2015 Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana goals,
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More informationA patient with acute on chronic liver failure
A patient with acute on chronic liver failure Dott.ssa Marta Cavallin Dept. of Medicine of University of Padova, Italy 6 th Post Meeting AISF Rome, 23 rd February 2013 Dott.ssa Marta Cavallin medico in
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationAASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble.
AASLD PRACTICE GUIDELINE The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension Thomas D. Boyer 1 and Ziv J. Haskal 2 Preamble The recommendations in this article
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationAlcoholic Liver Disease as First Indication
Alcoholic Liver Disease as First Indication Patrizia Burra Multivisceral Transplant Unit Gastroenterology Department of Surgery, Oncology and Gastroenterology Padua University Hospital, Padua, Italy Patrizia
More informationMANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS
MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationIs pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationBRTO /PARTO Indications and outcomes
BRTO /PARTO Indications and outcomes Saher Sabri, MD Associate Professor of Radiology and Surgery Division of Interventional Radiology University of Virginia Health System Saher Sabri, M.D. Speakers Bureau:
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationJMSCR Vol 04 Issue 08 Page August 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v4i8.23 Portal Hypertension in Adults- A Comprehensive
More informationV ariceal haemorrhage is a major cause of mortality and
270 LIVER DISEASE The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric : clinical and haemodynamic correlations D Tripathi, G Therapondos, E
More informationRole of Nutritional Support in the Treatment of Alcoholic Liver Disease
Riunione Monotematica AISF Alcoholic Liver Disease: The New Challenge Roma, 4-6 Ottobre 2017 Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Esmeralda Capristo Divisione di Patologie
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationRisk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis
Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong
More informationACUTE VARICEAL BLEEDING MULTIMODAL APPROACH
FALK symposium. Liver Cirrhosis: from pathophysiology to disease management Dresden, October 13-14 14 2007 ACUTE VARICEAL BLEEDING MULTIMODAL APPROACH Professor Andrew K Burroughs Hepato-biliary biliary-pancreatic
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationNONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE UPDATES NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW Mihaela Dimache 1,2*, Irina Gîrleanu 1,2,
More informationStaging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationManejo Actual del Sangrado por Varices Gástricas
Manejo Actual del Sangrado por Varices Gástricas Juan Carlos Garcia-Pagán Barcelona Hepatic Hemodynamic Laboratory. Liver Unit. IMDIM. Hospital Clinic. IDIBAPS. Ciberehd. XXIV Congreso de la Asociación
More informationTerlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationFactors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center
Factors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years Experience from a Single Tertiary Medical Center Jen-Jung Pan, MD, PhD, Chaoru Chen, PhD, James G. Caridi,
More informationReview Article Self-Expandable Metal Stents in the Treatment of Acute Esophageal Variceal Bleeding
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2011, Article ID 910986, 6 pages doi:10.1155/2011/910986 Review Article Self-Expandable Metal Stents in the Treatment of Acute
More informationDOTTORATO DI RICERCA IN SCIENZE MEDICO-CHIRURGICHE GASTROENTEROLOGICHE E DEI TRAPIANTI TITOLO TESI FACTORS PREDICTING MORTALITY AFTER TIPS FOR
Alma Mater Studiorum Università di Bologna DOTTORATO DI RICERCA IN SCIENZE MEDICO-CHIRURGICHE GASTROENTEROLOGICHE E DEI TRAPIANTI Ciclo XXII Settore/i scientifico-disciplinare/i di afferenza: MED/12 TITOLO
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationCARLO MERKEL, MASSIMO BOLOGNESI, DAVID SACERDOTI, GIANCARLO BOMBONATO, BARBARA BELLINI, RAFFAELLA BIGHIN, AND ANGELO GATTA
The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis CARLO MERKEL, MASSIMO BOLOGNESI,
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationThe role of TIPS in the management of liver transplant candidates
Original Article The role of TIPS in the management of liver transplant candidates United European Gastroenterology Journal 217, Vol. 5(8) 11 117! Author(s) 217 Reprints and permissions: sagepub.co.uk/journalspermissions.nav
More informationEDUCATION PRACTICE. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:931 935 EDUCATION PRACTICE Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? VANDANA KHUNGAR* and SAMMY SAAB*,
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationRisk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients
Oregon Health & Science University OHSU Digital Commons Scholar Archive 9-2014 Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients
More informationTreatment of portal hypertension in the light of the Baveno VI Consensus Conference
r e v I E w A R T I C l e S Curierul medical, December 2015, Vol. 58, No 6 Treatment of portal hypertension in the light of the Baveno VI Consensus Conference E. Tcaciuc Department of Internal Medicine,
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationUse of transjugular intrahepatic portosystemic shunt in liver disease
Vol. XVIII No. 3 JOURNAL OF VASCULAR NURSING PAGE 83 Use of transjugular intrahepatic portosystemic shunt in liver disease Patricia Ann Radovich, RN, MSN, CCRN, FCCM Persons with cirrhosis have many complications.
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationColangiocarcinoma on the rise!
Colangiocarcinoma on the rise! D. ALVARO, Univ. Sapienza, Rome, Italy. MONOTEMATICA AISF, The future of Liver Diseases, Milano 13-15 Ottobre 2016 Domenico ALVARO, MD. SAPIENZA, ROMA Il sottoscritto dichiara
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationMatching study design to research question-interactive learning session
Matching study design to research question-interactive learning session Rahul Mhaskar Assistant Professor Clinical and Translational Science Institute Division and Center for Evidence based Medicine and
More informationTitle: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana
More informationCost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R Record Status This is a critical abstract of an economic
More informationCIRRHOTIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationRiunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease
Riunione Monotematica AISF 2017 Roma 5 Ottobre 2017 Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Lorenzo Leggio, M.D., Ph.D., M.Sc. Lorenzo Leggio, M.D., Ph.D., M.Sc. Il
More information